Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Budapest - Delayed Quote HUF

Bayer Aktiengesellschaft (BAYER.BD)

Compare
9,440.00
+262.00
+(2.85%)
As of 9:23:39 AM GMT+1. Market Open.
Loading Chart for BAYER.BD
  • Previous Close 9,178.00
  • Open 9,440.00
  • Bid 9,472.00 x --
  • Ask 9,514.00 x --
  • Day's Range 9,440.00 - 9,440.00
  • 52 Week Range 7,675.00 - 12,292.00
  • Volume 11
  • Avg. Volume 228
  • Market Cap (intraday) 9.414T
  • Beta (5Y Monthly) 1.04
  • PE Ratio (TTM) --
  • EPS (TTM) -1,039.87
  • Earnings Date May 13, 2025
  • Forward Dividend & Yield 44.83 (0.49%)
  • Ex-Dividend Date Apr 28, 2025
  • 1y Target Est --

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed management as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular, renal, and gynecological diseases; collaboration agreement with Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.

www.bayer.com

90,587

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BAYER.BD

View More

Performance Overview: BAYER.BD

Trailing total returns as of 3/17/2025, which may include dividends or other distributions. Benchmark is DAX P .

YTD Return

BAYER.BD
18.95%
DAX P
15.41%

1-Year Return

BAYER.BD
9.94%
DAX P
28.10%

3-Year Return

BAYER.BD
57.81%
DAX P
59.69%

5-Year Return

BAYER.BD
57.81%
DAX P
157.04%

Compare To: BAYER.BD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAYER.BD

View More

Valuation Measures

Annual
As of 3/14/2025
  • Market Cap

    9.15T

  • Enterprise Value

    22.20T

  • Trailing P/E

    --

  • Forward P/E

    3.59

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.48

  • Price/Book (mrq)

    0.71

  • Enterprise Value/Revenue

    1.19

  • Enterprise Value/EBITDA

    6.30

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.48%

  • Return on Assets (ttm)

    3.00%

  • Return on Equity (ttm)

    -7.82%

  • Revenue (ttm)

    46.61B

  • Net Income Avi to Common (ttm)

    -2.55B

  • Diluted EPS (ttm)

    -1,039.87

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.09B

  • Total Debt/Equity (mrq)

    127.36%

  • Levered Free Cash Flow (ttm)

    5.47B

Research Analysis: BAYER.BD

View More

Company Insights: BAYER.BD

Research Reports: BAYER.BD

View More

People Also Watch